The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DHR | -1.26% | +6.13% | +1.2% | +62,575% |
| S&P | +14.29% | +86.82% | +13.3% | +7,569% |
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
The company's third-quarter earnings pleased investors.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $6.84B | 4.6% |
| Gross Profit | $3.97B | 2.0% |
| Gross Margin | 58.00% | -1.5% |
| Market Cap | $161.70B | -2.5% |
| Market Cap / Employee | $2.57M | 0.0% |
| Employees | 63K | 0.0% |
| Net Income | $1.18B | 8.9% |
| EBITDA | $2.13B | -9.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.62B | 122.1% |
| Accounts Receivable | $3.91B | 10.6% |
| Inventory | 2.5K | 6.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $18.42B | 11.8% |
| Short Term Debt | $2.00M | -99.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.47% | -0.3% |
| Return On Invested Capital | 7.22% | 0.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.73B | 15.2% |
| Operating Free Cash Flow | $2.10B | 4.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 39.91 | 42.22 | 38.04 | 45.35 | 4.47% |
| Price to Book | 2.98 | 2.78 | 2.71 | 3.17 | -2.04% |
| Price to Sales | 6.23 | 5.95 | 5.44 | 6.62 | -5.38% |
| Price to Tangible Book Value | -15.48 | -14.58 | -15.28 | -16.21 | 4.90% |
| Price to Free Cash Flow TTM | 36.04 | 35.32 | 31.64 | 37.26 | 0.94% |
| Enterprise Value to EBITDA | 87.22 | 87.94 | 79.15 | 83.09 | 6.74% |
| Free Cash Flow Yield | 2.8% | 2.8% | 3.2% | 2.7% | -0.93% |
| Return on Equity | 7.2% | 6.7% | 6.8% | 7.1% | -6.81% |
| Total Debt | $17.58B | $18.56B | $18.16B | $18.42B | 7.42% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
